nach oben

Journal of Immigrant and Minority Health

Erschienen in:

06.06.2016 | Original Paper

Distribution of IL28B Polymorphism in a Cohort of Italians and Immigrants with HCV Infection: Association with Viraemia, Stage of Fibrosis and Response to Treatment

verfasst von: L. Nosotti, A. Petrelli, D. Genovese, S. Catone, C. Argentini, S. Vella, A. Rossi, G. Costanzo, A. Fortino, L. Chessa, L. Miglioresi, C. Mirisola

Erschienen in: Journal of Immigrant and Minority Health | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Aims of the study are to investigate, in a cohort of patients affected by HCV chronic hepatitis with genotypes 1 and 4, the prevalence of interleukin 28B (IL28B) genotypes, the possible association between IL28B polymorphism and severity of liver damage, the role of IL28B CC as a predictor of outcome. 365 patients with HCV infection were observed between 2013 and 2014. Demographic, virological, biochemical, and genetic characteristics of each patient were investigated. Liver fibrosis was assessed by transient elastometry. Mean age of the patients (72.9 % males, 27.1 % females) is 50 years. 91.5 % % of patients are Caucasian, 8.5 % African. In the patients with HCV1 and HCV4 a higher frequency of IL28B CT is observed with a prevalence of 52.1 and 61.8 % respectively. As regards ethnic group, African people have a prevalence of 35.5 % for CC, while Caucasians have a prevalence of 23.8 % for CC. In our cohort, IL28B polymorphism does not show significant differences among ethnic groups and in HCV1 and HCV4 genotypes. As described in literature, IL28B CC genotype is confirmed as predictor of sustained virological response in both Caucasians and Africans. A significant correlation between liver fibrosis and IL28B polymorphism emerges.

Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29(Suppl. 1):74–81.CrossRefPubMed

Thompson AJ, Muir A, Sulkowski M, Ge D, Fellay J, Shianna KV, Urban T, et al. IL28B polymorphism improves viral kinetics and is the strongest pre-treatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010;139:120–9.CrossRefPubMed

Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, Mc Hutchison JG, Goldstein DB, Carrington M. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461:798–801.CrossRefPubMedPubMedCentral

Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399–401.CrossRefPubMed

Suppiah V, Maldovam M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, et al. IL 28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41:1100–4.CrossRefPubMed

Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakmoto N, Nakagawa M, Korenaga M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105–9.CrossRefPubMed

Asselah T, De Muynck S, Broet P, Masliah-Planchon J, et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol. 2012;56:527–32.CrossRefPubMed

Mangia A, Mottola L, Santoro R. Interleukin 28B plymorphisms as predictor of response in hepatitis C genotype 2 and 3 infected patients. World J Gastroenterol. 2013;19(47):8924–8.CrossRefPubMedPubMedCentral

Antaki N, Craxi A, Kamal S, Moucari R, Van der Merwe S, Haffar S, et al. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int. 2010;30:342–55.CrossRefPubMed

10.

Kamal SM. Hepatitis C virus genotype 4 therapy: progress and challenges. Liver Int. 2011;31:45–52.CrossRefPubMed

11.

Mangia A, Thompson AJ, Santoro R, et al. Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring. Hepatology. 2011;54:772–80.CrossRefPubMed

12.

Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, Shianna KV, Mottola L, Petruzzellis D, Bacca D, Carretta V, Minerva N, Goldstein DB, Mc Hutchison JG. Interleukin-28B polymorphism determines treatment response of patients with hepatitis C genotypes 2 and 3 who do not achieve a rapid virologic response. Gastroenterology. 2010;139:821–7.CrossRefPubMed

13.

Mc Carthy JJ, Li JH, Thompson A, Suchindran S, et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology. 2010;138:2307–14.CrossRef

14.

Eslam M, Leung R, Romero-Gomez M et al. IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection.

15.

Mottola L, Cenderello G, Piazzolla VA, Forte P, Carretta V, Mecenate F, Brancaccio G, Minisini R, Zuin M, Terreni N, Monti M, Colombo AE, Nosotti L, Minerva N, Luzzitelli I, Kostandini A, Cuccorese G, Russello M, Santoro R, Mangia A. Interleukin-28B genetic variants in untreated Italian HCV-infected patients: a multicentre study. Liver Int. 2015;35(2):482–8. doi:10.1111/liv.12630.CrossRefPubMed

16.

Abe H, Ochi H, Maekawa T, et al. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J Hepatol. 2010;53:439–43.CrossRefPubMed

17.

Barreiro P, Pineda JA, Rallon N, et al. Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy. J Infect Dis. 2011;203:1629–36.CrossRefPubMed

18.

Bochud PY, Bibert S, Kutalik Z, et al. IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology. 2012;55:384–94.CrossRefPubMed

19.

Ydreborg M, Westin J, Rembeck K, Lindh M, Norrgren H, Holmberg A, Wejstål R, Norkrans G, Cardell K, Weiland O, Lagging M. Impact of Il28b-related single nucleotide polymorphisms on liver transient elastography in chronic hepatitis C infection. PLoS One. 2013;8(11):e80172. doi:10.1371/journal.pone.0080172.eCollection.CrossRefPubMedPubMedCentral

20.

Fabris C, Falleti E, Cussigh A, et al. IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC. J Hepatol. 2011;54:716–22.CrossRefPubMed

21.

Marabita F, Aghemo A, De Nicola S, Rumi MG, Cheroni C, Scavelli R, Crimi M, Soffredini R, Abrignani S, De Francesco R, Colombo M. Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology. 2011;54(4):1127–34. doi:10.1002/hep.24503 Epub 2011 Aug 19.CrossRefPubMed

22.

Noureddin M, Wright EC, Alter H, et al. Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology. 2013;58:1548–57.CrossRefPubMedPubMedCentral

23.

Ansaldi F, Bruzzone B, Salmaso S, Rota MC, Durando P, Gasparini R, Icardi G. Different seroprevalence and molecular epidemiology patterns of hepatitis C virus infection in Italy. J Med Virol. 2005;76:327–32.CrossRefPubMed

24.

Marascio N, Liberto M, Barreca G, Zicca E, Quirino A, Lamberti A, Bianco G, Matera G, Surace L, Berardelli G, Surace L, De Maria V, Giancotti F, Leone R, Villella V, Nisticò S, Borelli A, Caruso V, Calderazzo M, Griffo G, Masciari R, Minchella P, Cosco L, Laganà C, Oliva A, Foti G, Fiorillo M, Bocchiaro G, Surace P, Ciccaglione A, Ciccozzi M, Cesario F, Torti C, Focà A. Update on epidemiology of HCV in Italy: focus on the Calabria Region. BMC Infect Dis. 2014;14(Suppl 5):S2. doi:10.1186/1471-2334-14-S5-S2.CrossRefPubMedPubMedCentral

25.

Derbala M, Rizk N, Shebl F, Alkaabi S, Eldweik N, John A, Sharma M, Yaqoob R, Almohanadi M, Butt M, Alejji K. Interleukin-28 and hepatitis C virus genotype-4: treatment-induced clearance and liver fibrosis. World J Gastroenterol. 2012;18(47):7003–8. doi:10.3748/wjg.v18.i47.7003.CrossRefPubMedPubMedCentral

26.

Muir AJ, Arora S, Everson G, Flisiak R, George J, Ghalib R, Gordon SC, Gray T, Greenbloom S, Hassanein T, Hillson J, Horga MA, Jacobson IM, Jeffers L, Kowdley KV, Lawitz E, Lueth S, Rodriguez-Torres M, Rustgi V, Shemanski L, Shiffman ML, Srinivasan S, Vargas HE, Vierling JM, Xu D, Lopez-Talavera JC, Zeuzem S. EMERGE study group. A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. J Hepatol. 2014;61(6):1238–46. doi:10.1016/j.jhep.2014.07.022.CrossRefPubMed

27.

Tamaki N, Kurosaki M, Higuchi M, Takada H, Nakakuki N, Yasui Y, et al. Genetic polymorphism of IL28B and PNPLA3 are predictive for HCV related rapid fibrosis progression and identify patients who require urgent antiviral treatment with new regimens. PLoS One. 2015;10(9):e0137351. doi:10.1371/journal.pone.0137351.CrossRefPubMedPubMedCentral

28.

European Medicines Agency (EMA). Sovaldi registration details. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002798/human med 001723.jsp&mid = WC0b01ac058001d124. Accessed 06 Feb 2015.

29.

U.S. Food and Drug Administration (FDA). Sovaldi registrationdetails. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search. DrugDetails. Accessed 12 Feb 2015.

30.

European Medicines Agency (EMA). Harvoni registration details. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003850/human med 001813.jsp&mid = WC0b01ac058001d124. Accessed 06 Feb 15.

31.

U.S. Food and Drug Administration (FDA). Harvoni registrationdetails. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails.

32.

European Medicines Agency (EMA). Daklinza registration details. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003768/human med 001792.jsp&mid = WC0b01ac058001d124. Accessed 06 Feb 15.

33.

European Medicines Agency (EMA). Olysio registration details. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002777/human med 001766.jsp&mid = WC0b01ac058001d124. Accessed 06 Feb 2015.

34.

U.S. Food and Drug Administration (FDA). Olysio registrationdetails. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails.

35.

U.S. Food and Drug Administration (FDA). Viekirax^® + Exviera registra-tion details. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails.

36.

Fried MW, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson I, Marcellin P, Manns M, Nikitin I, Poordad F, Sherman M, Zeuzem S, Scott J, Gilles L, Lenz O, Peeters M, Sekar V, De Smedt G, Beumont-Mauviel M. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology. 2013;58(6):1918–29. doi:10.1002/hep.26641.CrossRefPubMedPubMedCentral

37.

Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878–87. doi:10.1056/NEJMoa1214853.CrossRefPubMed

Titel: Distribution of IL28B Polymorphism in a Cohort of Italians and Immigrants with HCV Infection: Association with Viraemia, Stage of Fibrosis and Response to Treatment
verfasst von: L. Nosotti
A. Petrelli
D. Genovese
S. Catone
C. Argentini
S. Vella
A. Rossi
G. Costanzo
A. Fortino
L. Chessa
L. Miglioresi
C. Mirisola
Publikationsdatum: 06.06.2016
Verlag: Springer US
Erschienen in: Journal of Immigrant and Minority Health / Ausgabe 4/2017
Print ISSN: 1557-1912
Elektronische ISSN: 1557-1920
DOI: https://doi.org/10.1007/s10903-016-0444-9

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2017

Medicaid Expansion and Healthcare Access: Lessons from Asian American and Pacific Islander Experiences in California

U.S. Citizen Children of Undocumented Parents: The Link Between State Immigration Policy and the Health of Latino Children

Self-efficacy for HIV Prevention Among Refugee Hispanic Women in South Florida

Evidence of Local HIV Transmission in the African Community of King County, Washington

Health and Socio-Cultural Experiences of Refugee Women: An Integrative Review

Acceptability of Rapid HIV Testing Among Latinos in Washington Heights, New York City, New York, USA